Researchers of a phase 2a study found that the topical phosphodiesterase 4 inhibitor PF-07038124 was well tolerated and demonstrated superior efficacy compared with placebo in treating patients with mild-to-moderate atopic dermatitis (AD) and plaque psoriasis. The study, conducted across 34 sites in 4 countries from December 2020 to August 2021, involved 104 participants aged 18 to 70 years. They were randomized to receive either a once-daily dose of PF-07038124 or a vehicle control for six weeks, followed by a 4- to 5-week safety follow-up period. The primary endpoint for patients with plaque psoriasis was the change from baseline in the Psoriasis Area and Severity Index (PASI) score at six weeks.
The results showed significant improvements in the PF-07038124 groups compared with control groups. PASI scores improved markedly, with a change from baseline of -4.8 vs 0.1 in the control group. The number of patients who experienced treatment-emergent adverse events was comparable between the treatment and control groups, with no application site reactions reported for PF-07038124. The researchers concluded that PF-07038124 was well tolerated, with no significant systemic absorption leading to serious adverse events or changes in chronic health conditions, demonstrating its potential as an effective treatment for AD and plaque psoriasis with minimal side effects.
Reference: Steinzor P. PF-07038124 Demonstrates Superior Efficacy in Mild to Moderate Atopic Dermatitis, Plaque Psoriasis. Dermatology Times. Published January 8, 2024. Accessed March 13, 2024. https://www.dermatologytimes.com/view/pf-07038124-demonstrates-superior-efficacy-in-mild-to-moderate-atopic-dermatitis-plaque-psoriasis
